OverweightNCT07889570
A Controlled Study to Evaluate the Effects of a Supplement on Weight Loss, Blood Sugar, and Appetite Suppression
A study testing Evolv GLP-1 Group in people with Overweight and Obesity, run by Evolv at 1 site in United States.
Trial summary
This is a randomized, controlled, hybrid clinical trial evaluating the effects of the Evolv GLP-1 supplement on weight loss, blood sugar regulation, and appetite suppression over 12 weeks. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Overweight, Obesity, Blood Sugar Regulation
- What is being tested?
- Evolv GLP-1 Group
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 98 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Apr 2026to 1 Jul 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Be male or female
- Be aged 18+
- BMI of 25-29.9 kg/m2
- Anyone with concerns regarding all of the following for the past 12 weeks: weight management and food cravings and/or appetite management
- Must not be living with any uncontrolled chronic disease
- Not currently taking, and not planning to take for the duration of the test period, any products, prescription medications, herbal remedies, over-the-counter medications, or supplements that target blood sugar regulation, weight, or appetite
Show all 9Show fewer
- Willing to maintain their current sleep schedule and activity level for the duration of the study
- Resides in the United States
- Not currently partaking in another research study and will not be partaking in any other research study for the next 12 weeks or at any point during this study's duration
Who cannot join
- Diagnosed with Type 1 diabetes, any metabolic or endocrine disorder, or any disorder that affects blood sugars (e.g., hypothyroidism, Hashimoto's thyroiditis)
- Diagnosed with Type 2 diabetes mellitus (T2DM) and have been prescribed metformin, insulin, Sulfonylureas, Meglitinides, SGLT2 inhibitors and/or GLP-1 medications including Wegovy, Ozempic, Rybelsus, Saxenda, Victoza, Zepbound, Byetta, Bydureon, Trulicity, or Adlyxin
- Current use or past history of use within the last 2 months (8 weeks) of corticosteroids including Deltasone, Orapred, Prelone, Medrol, Qvar, Celestone, Decadron, Cortef, or Kenalog
- Current use or past history of use within the last 2 months (8 weeks) of immunosuppressants including Tacrolimus (Prograf), Cyclosporine (Neoral), or Sirolimus (Rapamune)
- Anyone who has been treated with any antibiotic or antifungal prescription medication in the last 2 months (8 weeks)
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including cancer, liver, and psychiatric disorders
Show all 16Show fewer
- Is currently undergoing or planning to undergo any significant medical procedures in the next six months
- Anyone who has undergone any surgeries or invasive treatments in the last six months, or has any planned during the study period
- Has had any major illness in the last three months
- Anyone with known severe allergic reactions, including those requiring the use of an Epi-pen
- Anyone with any allergies or sensitivities to any of the study product ingredients
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period)
- Heavy drinkers or drug users (a heavy drinker is considered to be a woman who drinks 8 or more alcoholic drinks per week or a man who drinks 15 or more alcoholic drinks per week)
- Anyone unwilling to follow the study protocol
- Anyone with a history of substance abuse
- Anyone who is currently a smoker or has been a smoker in the past 3 months
Trial locations and contacts
1 site in 1 country.
About this study
This is a randomized, controlled, hybrid clinical trial evaluating the effects of the Evolv GLP-1 supplement on weight loss, blood sugar regulation, and appetite suppression over 12 weeks. Participants are randomized to either the intervention group (8 capsules daily) or a control group receiving standardized healthy eating guidance from the American Diabetes Association.
The study enrolls 98 male and female participants aged 18 and older with a BMI of 25-29.9 kg/m2. Primary endpoints include Hemoglobin A1c (HgbA1c) measured via bloodwork at Baseline, Week 6, and Week 12, as well as body weight and waist circumference measurements collected at Baseline, Week 4, Week 6, Week 8, and Week 12. Secondary endpoints capture participant perceptions of appetite suppression, weight loss, blood sugar, and overall well-being via self-reported questionnaires at the same time points.
- Being tested
- Evolv GLP-1 Group, Control Group
- Medical subject headings
- Overweight, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Evolv GLP-1 GroupDietary supplement
Participants take 8 capsules of Evolv GLP-1 daily (4 capsules in the morning and 4 capsules in the evening) for 12 weeks.
Control GroupOther
Participants receive a standardized recommendation for healthy eating from the American Diabetes Association (https://diabetesfoodhub.org/blog/what-diabetes-plaand do not receive any study product.
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group | Experimental | Not described Receives: Dietary Supplement: Evolv GLP-1 Group |
| Control Group | Placebo comparator | Not described Receives: Other: Control Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Hemoglobin A1c (HgbA1c)
Change from Baseline in HgbA1c measured via blood draw at a Labcorp location center
Measured: Baseline, Week 6, and Week 12
Change in Body Weight
Change from Baseline in body weight measured at home using a provided Withings scale; average of three consecutive daily measurements taken at each time point
Measured: Baseline, Week 4, Week 6, Week 8, and Week 12
Change in Waist Circumference
Change from Baseline in waist circumference measured at home using a provided tape measure
Measured: Baseline, Week 4, Week 6, Week 8, and Week 12
Secondary outcomes (4)
Participant Perception of Effect on Weight Loss
Self-reported perception of the product's effect on weight loss assessed via study-specific questionnaire
Measured: Baseline, Week 4, Week 6, Week 8, and Week 12
Participant Perception of Effect on Appetite Suppression
Self-reported perception of the product's effect on appetite suppression including curbing cravings assessed via study-specific questionnaire
Measured: Baseline, Week 4, Week 6, Week 8, and Week 12
Participant Perception of Effect on Blood Sugar
Self-reported perception of the product's effect on blood sugar assessed via study-specific questionnaire
Measured: Baseline, Week 4, Week 6, Week 8, and Week 12
Participant Perception of Effect on Overall Well-Being
Self-reported perception of the product's effect on other outcomes related to well-being assessed via study-specific questionnaire
Measured: Baseline, Week 4, Week 6, Week 8, and Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2026
- Study start1 Apr 2026
- Primary completion1 Jul 2026
- Study completion1 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OverweightStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 98 participants (actual)
Sponsor and investigators
- Lead sponsor
- Evolv
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07889570
- Sponsor's protocol ID
- 20692
- Status last verified
- Oct 2026
- First submitted
- 16 Oct 2026
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Controlled Study to Evaluate the Effects of a Supplement on Weight Loss, Blood Sugar, and Appetite Suppression
- ClinicalTrials.gov ID
- NCT07889570
- Acronym / sponsor ID
- 20692
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 98 participants (actual)
- Lead sponsor
- EvolvIndustry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 1 Apr 2026 (actual)
- Primary completion
- 1 Jul 2026 (actual)
- Study completion
- 1 Jul 2026 (actual)
- First posted
- 22 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized, controlled, hybrid clinical trial evaluating the effects of the Evolv GLP-1 supplement on weight loss, blood sugar regulation, and appetite suppression over 12 weeks. Participants are randomized to either the intervention group (8 capsules daily) or a control group receiving standardized healthy eating guidance from the American Diabetes Association.
The study enrolls 98 male and female participants aged 18 and older with a BMI of 25-29.9 kg/m2. Primary endpoints include Hemoglobin A1c (HgbA1c) measured via bloodwork at Baseline, Week 6, and Week 12, as well as body weight and waist circumference measurements collected at Baseline, Week 4, Week 6, Week 8, and Week 12. Secondary endpoints capture participant perceptions of appetite suppression, weight loss, blood sugar, and overall well-being via self-reported questionnaires at the same time points.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention Group | Experimental | Dietary Supplement: Evolv GLP-1 Group |
| Control Group | Placebo comparator | Other: Control Group |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Be male or female
- Be aged 18+
- BMI of 25-29.9 kg/m2
- Anyone with concerns regarding all of the following for the past 12 weeks: weight management and food cravings and/or appetite management
- Must not be living with any uncontrolled chronic disease
Key exclusion criteria (16 listed)
- Diagnosed with Type 1 diabetes, any metabolic or endocrine disorder, or any disorder that affects blood sugars (e.g., hypothyroidism, Hashimoto's thyroiditis)
- Diagnosed with Type 2 diabetes mellitus (T2DM) and have been prescribed metformin, insulin, Sulfonylureas, Meglitinides, SGLT2 inhibitors and/or GLP-1 medications including Wegovy, Ozempic, Rybelsus, Saxenda, Victoza, Zepbound, Byetta, Bydureon, Trulicity, or Adlyxin
- Current use or past history of use within the last 2 months (8 weeks) of corticosteroids including Deltasone, Orapred, Prelone, Medrol, Qvar, Celestone, Decadron, Cortef, or Kenalog
- Current use or past history of use within the last 2 months (8 weeks) of immunosuppressants including Tacrolimus (Prograf), Cyclosporine (Neoral), or Sirolimus (Rapamune)
- Anyone who has been treated with any antibiotic or antifungal prescription medication in the last 2 months (8 weeks)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Evolv GLP-1 GroupParticipants take 8 capsules of Evolv GLP-1 daily (4 capsules in the morning and 4 capsules in the evening) for 12 weeks. | Dietary supplement | Intervention Group |
| Control GroupParticipants receive a standardized recommendation for healthy eating from the American Diabetes Association (https://diabetesfoodhub.org/blog/what-diabetes-plaand do not receive any study product. | Other | Control Group |
Primary outcome
Change in Hemoglobin A1c (HgbA1c)
Time frame: Baseline, Week 6, and Week 12
Change from Baseline in HgbA1c measured via blood draw at a Labcorp location center
Change in Body Weight
Time frame: Baseline, Week 4, Week 6, Week 8, and Week 12
Change from Baseline in body weight measured at home using a provided Withings scale; average of three consecutive daily measurements taken at each time point
Change in Waist Circumference
Time frame: Baseline, Week 4, Week 6, Week 8, and Week 12
Change from Baseline in waist circumference measured at home using a provided tape measure
4 secondary outcomes
Participant Perception of Effect on Weight Loss
Time frame: Baseline, Week 4, Week 6, Week 8, and Week 12
Participant Perception of Effect on Appetite Suppression
Time frame: Baseline, Week 4, Week 6, Week 8, and Week 12
Participant Perception of Effect on Blood Sugar
Time frame: Baseline, Week 4, Week 6, Week 8, and Week 12
Participant Perception of Effect on Overall Well-Being
Time frame: Baseline, Week 4, Week 6, Week 8, and Week 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
Related trials for Overweight
Not yet recruiting
Transcutaneous Auricular Vagus Nerve Stimulation Combined With Lifestyle Intervention for Visceral Fat Reduction in Adults With Overweight or Obesity
Overweight, Obesity
Not yet recruitingObservational study
Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism
Healthy Volunteer, Obestity
RecruitingPhase 1/2
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Not yet recruitingPhase 3
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
Not yet recruitingObservational study
A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity
Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Evolv GLP-1 Group in people with Overweight and Obesity, run by Evolv at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Hemoglobin A1c (HgbA1c) (time frame: Baseline, Week 6, and Week 12). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.